Xeris Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 9, 2020
November 02 2020 - 07:00AM
Business Wire
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty
pharmaceutical company leveraging its novel formulation technology
platforms to develop and commercialize ready-to-use injectable and
infusible drug formulations, today announced that the Company will
release its third quarter 2020 financial results before the open of
the U.S. financial markets on Monday, November 9, 2020. Management
will host a conference call and webcast at 8:30 a.m. ET that day to
discuss the Company’s financial and operational results.
To register for this conference call, please use this link
http://www.directeventreg.com/registration/event/5476709.
After registering, a confirmation email will be sent, including
dial-in details and a unique code for entry. To register for the
webcast, visit Xeris’ website at www.xerispharma.com. The Company
recommends registering a day in advance, or at minimum ten minutes
prior to the start of the call.
Following the conference call, a replay will be available at
(800) 585-8367 or (416) 621-4642 Conference ID: 5476709. An
archived webcast of this conference call will also be available
Xeris’ website.
About Xeris Pharmaceuticals, Inc.
Xeris (Nasdaq: XERS) is a specialty pharmaceutical company
delivering innovative solutions to simplify the experience of
administering important therapies that people rely on every day
around the world.
With a novel technology platform that enables ready-to-use,
room-temperature stable formulations of injectable and infusible
therapies, the company is advancing a portfolio of solutions in
various therapeutic categories, including its first commercial
product, Gvoke®. Its proprietary XeriSol™ and XeriJect™ formulation
technologies have the potential to offer distinct advantages over
conventional product formulations, including eliminating the need
for reconstitution, enabling long-term, room-temperature stability,
significantly reducing injection volume, and eliminating the
requirement for intravenous (IV) infusion. With Xeris’ technology,
new product formulations are designed to be easier to use by
patients, caregivers, and health practitioners and help reduce
costs for payers and the healthcare system.
Xeris is headquartered in Chicago, IL. For more information,
visit www.xerispharma.com, or follow us on Twitter, LinkedIn or
Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201102005055/en/
Allison Wey Senior Vice President, Investor Relations and
Corporate Communications awey@xerispharma.com 312-736-1237
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From Mar 2023 to Mar 2024